{
  "id": 1577655,
  "title": "Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock",
  "url": "https://urgent.news/2026/08/17/rhythm-pharmaceuticals-cso-alastair-garfield-sells-912-703-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T22:31:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/rhythm-pharmaceuticals-cso-alastair-garfield-sells-912703-in-stock-93CH-4864077"
  },
  "original_language": "en",
  "account": "Rhythm Pharmaceuticals' Chief Scientific Officer, Alastair Garfield, divested a total of 7,763 shares of the company's common stock on August 13, 2026, garnering a sum of $912,703. The shares were disposed of in several transactions at prices fluctuating between $115.67 and $119.52 per share. As of the current valuation, Rhythm Pharmaceuticals' stock trades at $115.55, closely hovering near its 52-week peak of $122.20. According to InvestingPro's assessment, the stock is considered overvalued, positioning it among companies featured on the Most Overvalued list. These transactions were carried out under a Rule 10b5-1 trading plan that Mr. Garfield initiated on May 14, 2026. Post these sales, Mr. Garfield retains a personal stake of 2,295 shares in Rhythm Pharmaceuticals common stock. Subscribers of InvestingPro gain access to an array of 13 ProTips for RYTM, complemented by a detailed Pro Research Report that distills intricate data into practical insights for this $7.94 billion biotech entity. Apart from this, Rhythm Pharmaceuticals disclosed a stronger-than-anticipated earnings report and revenue for the second quarter of 2026. The company incurred a loss of $0.73 per share, marginally better than the estimated loss of $0.81 per share. Revenue clocked in at $71.26 million, outpacing Wall Street's forecast of $67.53 million. This accomplishment was propelled by the successful introduction of IMCIVREE, designed to combat hypothalamic obesity, and sustained expansion in therapies for Bardet-Biedl syndrome. Furthermore, Citizens upped its price target for Rhythm Pharmaceuticals shares from $155 to $160, preserving a Market Outperform rating. This upgrade was credited to the robust launch of Imcivree, propelled by substantial patient demand. The company's management also reported over 400 sign-ups for Imcivree as of the second quarter, exceeding their initial projection of 350. These advancements underscore Rhythm Pharmaceuticals' optimistic trajectory in the market. This account was AI-generated and subsequently vetted by a human editor. For further details, refer to the Terms and Conditions.",
  "summary": null,
  "key_points": [
    "Rhythm Pharmaceuticals CSO Alastair Garfield sold 7,763 shares worth $912,703",
    "Shares sold at prices between $115.67 and $119.52 per share on August 13, 2026",
    "Garfield retains 2,295 shares; stock considered overvalued by InvestingPro"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}